查看文章

Deposition of amyloid β protein (Aβ)is one of the characteristic features of Alzheimer's disease (AD) neuropathology. Beta‐secretase, a β‐site APP cleaving enzyme 1 (BACE1), is essential for A β biosynthesis. Although inhibition of BACE1 is considered a valid therapeutic target for AD, the enzymatic dynamics of BACE1 in regulating APP processing and A β generation has not yet been fully defined. To examine this issue, tightly controlled inducible BACE1 gene expression was established in the neuronal cell line N2ABP1 and the non‐neuronal cell line E2BP1 using an ecdysone‐inducible system. The BACE1 protein level was increased in a time‐and dosage‐dependent manner in the inducible BACE1 stable cells by treatment with inducer ponasterone A. The generation of APP CTFβ, the β‐secretase product, increased proportionally with the level of BACE1 protein expression. However, Aβ40/42 production …